| Literature DB >> 25144185 |
Paltu Kumar Dhal1, Ranjan Kumar Barman1, Sudipto Saha2, Santasabuj Das3.
Abstract
BACKGROUND: Salmonella Typhi is a human-restricted pathogen, which causes typhoid fever and remains a global health problem in the developing countries. Although previously reported host expression datasets had identified putative biomarkers and therapeutic targets of typhoid fever, the underlying molecular mechanism of pathogenesis remains incompletely understood.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25144185 PMCID: PMC4140748 DOI: 10.1371/journal.pone.0104911
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
GEO series (GSE) datasets used in this study.
| GEO accession no | No of Sample | Description | Abbreviation | References |
| GSE28658 | 3×2 | Peripheral blood sample of | STA Vs STC |
|
| GSE28658 | 3×2 | Peripheral blood sample of bacteremic (infection | BMA Vs BMC |
|
| GSE43838 | 6 | Blood sample of patients after and before 24 h | ECI Vs ECC |
|
| GSE40586 | 16 | Peripheral blood sample of the patients infected and uninfected with | SPI Vs SPC | Unpublished |
| GDS3057 | 12 | Leukemic blasts from acute myeloid leukemia (AML) patients with normal hematopoietic cells | MLDVsNHC |
|
Characteristics of protein-protein interaction network used in this study.
| Characteristics | No. of hubs | Interactions | Clustering Coefficient | Network Density | |
| Nodes | Edges | ||||
| Protein-protein interaction network from HPRD | 9617 | 39240 | 0.102 | 0.001 | |
| Protein-protein interaction network from HPRD with degree K≥5 | 4071 | 8850 | 28811 | 0.136 | 0.003 |
| Common hubs having expression profile across five GEO studies | 3025 | 8120 | 17261 | 0.133 | 0.004 |
| Specific hubs for | 81 | 1091 | 1343 | 0.034 | 0.002 |
Figure 1Salmonella Typhi infection specific dynamic subnetworks.
Co-expression merged with protein interaction networks, specifically altered during acute phase of S. Typhi infection. The round and diamond shaped nodes represent the hubs and their interacting partners, respectively. Out of 81, 6 yellow coloured hubs (IL2RA, SKP2, CIT, DTNA, CUL4A and SOCS7) represent increased Avg. PCC, while reaming 75 violet coloured (∼93%) hubs had decreased Avg. PCC during acute phase of S. Typhi infection.
Significantly enriched gene ontology biological process term analysis of 8 hubs and their interactors using DAVID database.
| Hub | Interactors | GO Term | FDR |
| CCR1 | CCL3, CCL4, CCL5, CCR1, PLP2, CREB3, JAK1, STAT1, STAT3, CCL26, CCL2, CCL7, CCL14, CCL15, CCL16, CCL3L1, CCL8, CCL23, GNA14, TPST1, TPST2 | GO:0006935∼chemotaxis | 1.82×10−18 |
| CD3E |
| GO:0007166∼cell surface receptor linked signal transduction | 1.9×10−04 |
| DUSP1 | DUSP1,MAPK14,HSPA4,SKP2,CKS1B,MAPK1,UBB,MAPK8,MAPK3,MAPK12 | GO:0007265∼Ras protein signal transduction | 0.049 |
| FCGR2B | FCGR2B,PTPN6,INPPL1,LY6E,CRP,C14orf1,INPP5D,APCS,LYN,BLK,MAPK1,MAPK3 | NA | NA |
| IRS2 | IRS2,PIK3R1,PLCG1,PTPN11,TYK2,ATP2A1,BCL2L1,JAK3,SHC1,UBTF,PTPN6,PIK3CD,PIK3R2,SOCS1,PIK3R3,SOCS7,NTRK1,EPOR,IGF1R,IL4R,JAK1,PTPRF,GRB2,YWHAZ,YWHAE,SOCS6,YWHAG,SOCS3,JAK2,ATP2A2,MPL,CRK,PIK3CA,FES,YWHAB,INSR | GO:0006793∼phosphorus metabolic process | 7.66×10−05 |
| NOTCH3 | NOTCH3,PSEN2,MAML2,MAML3,CHUK,RBPJ,JAG1,JAG2,SNW1,MAML1,DLL1,KAT2B,PSEN1 | GO:0007219∼Notch signaling pathway | 2.72×10−17 |
| PRKCA | KIT, OPRD1, RHOA, SPP1, PAM, PFKFB2, KCNE1, PTPN11, PRKCA, RRAD, RHO, DDX5, SRC, TP53, VCL, VTN, NCF1, GJB1, RPL10, ITGB2, PTPN12, SNAP25, NFATC1, DLX3, CASR, GPM6A, DGKZ, ADD3, GMFB, PA2G4, NRGN, DNM1, PLD1, HAND1, CFTR, CYTH2, RGS7, SNAP23, OCLN, STXBP1, SPAG1, PEA15, GRM1, RGS19, CD163, TRPV6, GSK3A, PLCB1, HSPB8, PEBP1, CHAT, MARCKS, PRKG1, PTGIR, EDF1, ADAP1, TNNI3, HABP4, GABRR1, TRPC3, PPP1R14A, THOC5, GRIA2, HMGB1, RARA, SDC4, TNNT2, ATP2B1, ADRBK1, PTPN6, SLC6A9, KCNQ2, GRM5, F11R, CDC42, ATP2B2, CBL, SHC1, DGKD, ACTA1, GJA1, DVL2, CREM, CORO1B, EZR, TOP2A, FLNC, RALBP1, EEF1D, EGFR, EIF4E, EWSR1, SLC1A1, ITGB1, GABRG2, GFAP, GRIA4, GRIA1, GRIN2B, GRIN2A, GFPT1, GNA15, HES1, HSPA1A, SDC2, HLA-A, CD9, ADRA1B, ITPKA, ITPKB, INSR, KRT18, LMNA, LMNB1, BCL2, ANXA2, CD5, LCK, MGMT, MBP, MYOD1, NOS1, APLP2, HMGN2, HMGN1, RAF1, GNB2L1, PRKCZ, SCTR, SEMG1, SEMG2, TERT, XK, SYK, TIAM1, AVPR1A, RGS2, MYLK, C1QBP, YWHAZ, BTG2, TEP1, ARHGEF1, OGG1, RAC1, PLD2, HAND2, CISH, FSCN1, DLG4, GNA12, AKAP5, AKAP12, YWHAG, POLB, ADCY5, SDPR, KCNE4, AFAP1, TRIM29, PDLIM7, STXBP3, GABRR2, BTK, ANXA7, FAS, ITGB4, PICK1, PPARA, FLNA, NUMB, HSP90AA1, ENTPD5 | GO:0044093∼positive regulation of molecular function, GO:0043549∼regulation of kinase activity, GO:0043067∼regulation of programmed cell death | 6.77×1006 |
| PYCARD | PYCARD,MEFV,SRF,NLRP3,NLRC4,CASP1,NLRP12,PRKAR1A,NLRP1,PYDC2,POP1 | GO:0006919∼activation of caspase activity | 3.71×10−05 |
Significantly enriched biological pathway (P value ≤0.05) analysis of 8 hubs and their interactors by the CluGO plug-in (using both KEGG_24.05.2012 and REACTOME_10.07.2012) of Cytoscape_v3.0.1.
| Hub | Interactors | REACTOM | KEGG | ||
| Pathways | PValue | Pathways | PValue | ||
| CCR1 | CCL3, CCL4, CCL5, CCR1, PLP2, CREB3, JAK1, STAT1, STAT3, CCL26, CCL2, CCL7, CCL14, CCL15, CCL16, CCL3L1, CCL8, CCL23, GNA14, TPST1, TPST2 | Peptide ligand-binding receptors, Chemokine receptors bind chemokines, Regulation of IFNG signalling and Interleukin-6 signaling | 2.89×10−10 to 1.85×10−06 | Cytokine-cytokine receptor interaction and Chemokine signaling pathway | 7.97×10−15 and 7.40×10−21 |
| CD3E |
| TCR signalling, Downstream TCR signalling and Generation of second messenger molecules | 2.14×10−14 to 6.89×10−11 | ErbB signaling pathway, T cell receptor signaling pathway and Primary immunodeficiency | 1.62×10−05 to 5.05×10−07 |
| DUSP1 | DUSP1,MAPK14,HSPA4,SKP2,CKS1B,MAPK1,UBB,MAPK8,MAPK3,MAPK12 | Toll-like receptor signalling pathway, Fc epsilon RI signaling pathway and Salmonella infection | 2.52×10−07 to 1.07×10−07 | Toll Like Receptor 3 (TLR3) Cascade and MyD88:Mal cascade initiated on plasma membrane | 8.30×10−07 and 1.16×10−06 |
| FCGR2B | FCGR2B,PTPN6,INPPL1,LY6E,CRP,C14orf1,INPP5D,APCS,LYN,BLK,MAPK1,MAPK3 | Signaling by Interleukins, Signaling by SCF-KIT and Growth hormone receptor signaling | 2.11×10−07 to 1.94×10−08 | B cell receptor signaling pathway and Fc gamma R-mediated phagocytosis | 3.68×10−14 and 8.46×10−11 |
| IRS2 | IRS2,PIK3R1,PLCG1,PTPN11,TYK2,ATP2A1,BCL2L1,JAK3,SHC1,UBTF,PTPN6,PIK3CD,PIK3R2,SOCS1,PIK3R3,SOCS7,NTRK1,EPOR,IGF1R,IL4R,JAK1,PTPRF,GRB2,YWHAZ,YWHAE,SOCS6,YWHAG,SOCS3,JAK2,ATP2A2,MPL,CRK,PIK3CA,FES,YWHAB,INSR | Cytokine Signaling in Immune system, Signaling by Interleukins and Interleukin-3, 5 and GM-CSF signaling | 3.97×10−20 to 4.15×10−23 | Jak-STAT signaling pathway, Neurotrophin signaling pathway, Insulin signaling pathway and Epstein-Barr virus infection | 1.48×10−22 to 1.63×10−11 |
| NOTCH3 | NOTCH3,PSEN2,MAML2,MAML3,CHUK,RBPJ,JAG1,JAG2,SNW1,MAML1,DLL1,KAT2B,PSEN1 | Signaling by NOTCH and Regulated proteolysis of p75NTR | 6.24×10−21 and 2.10×10−04 | Notch signaling pathway | 9.62×10−26 |
| PRKCA | KIT, OPRD1, RHOA, SPP1, PAM, PFKFB2, KCNE1, PTPN11, PRKCA, RRAD, RHO, DDX5, SRC, TP53, VCL, VTN, NCF1, GJB1, RPL10, ITGB2, PTPN12, SNAP25, NFATC1, DLX3, CASR, GPM6A, DGKZ, ADD3, GMFB, PA2G4, NRGN, DNM1, PLD1, HAND1, CFTR, CYTH2, RGS7, SNAP23, OCLN, STXBP1, SPAG1, PEA15, GRM1, RGS19, CD163, TRPV6, GSK3A, PLCB1, HSPB8, PEBP1, CHAT, MARCKS, PRKG1, PTGIR, EDF1, ADAP1, TNNI3, HABP4, GABRR1, TRPC3, PPP1R14A, THOC5, GRIA2, HMGB1, RARA, SDC4, TNNT2, ATP2B1, ADRBK1, PTPN6, SLC6A9, KCNQ2, GRM5, F11R, CDC42, ATP2B2, CBL, SHC1, DGKD, ACTA1, GJA1, DVL2, CREM, CORO1B, EZR, TOP2A, FLNC, RALBP1, EEF1D, EGFR, EIF4E, EWSR1, SLC1A1, ITGB1, GABRG2, GFAP, GRIA4, GRIA1, GRIN2B, GRIN2A, GFPT1, GNA15, HES1, HSPA1A, SDC2, HLA-A, CD9, ADRA1B, ITPKA, ITPKB, INSR, KRT18, LMNA, LMNB1, BCL2, ANXA2, CD5, LCK, MGMT, MBP, MYOD1, NOS1, APLP2, HMGN2, HMGN1, RAF1, GNB2L1, PRKCZ, SCTR, SEMG1, SEMG2, TERT, XK, SYK, TIAM1, AVPR1A, RGS2, MYLK, C1QBP, YWHAZ, BTG2, TEP1, ARHGEF1, OGG1, RAC1, PLD2, HAND2, CISH, FSCN1, DLG4, GNA12, AKAP5, AKAP12, YWHAG, POLB, ADCY5, SDPR, KCNE4, AFAP1, TRIM29, PDLIM7, STXBP3, GABRR2, BTK, ANXA7, FAS, ITGB4, PICK1, PPARA, FLNA, NUMB, HSP90AA1, ENTPD5 | Hemostasis, Platelet activation, signaling and aggregation, Transmission across Chemical Synapses and Gastrin-CREB signalling pathway via PKC and MAPK | 3.08×10−11 to 3.33×10−05 | Focal adhesion, Calcium signaling pathway, Glutamatergic synapse, Regulation of actin cytoskeleton, Chemokine signaling pathway, Endocytosis, Bacterial invasion of epithelial cells and Natural killer cell mediated cytotoxicity | 1.68×10−07 to 1.07×10−05 |
| PYCARD | PYCARD,MEFV,SRF,NLRP3,NLRC4,CASP1,NLRP12,PRKAR1A,NLRP1,PYDC2,POP1 | Inflammasomes and Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 2.07×10−15 and 1.37×10−12 | NOD-like receptor signaling pathway | 4.12×10−11 |
Figure 2Network of the interacting partners of CCR1 representing the differences in dynamic network properties during S. Typhi infection.
The edges were labelled with respective PCC values of individual interactors during different perturbances. The four conditions mentioned are A. Control (normal host cell), B. S. Typhi infection, C. other bacteremic (non-typhoid Salmonella, Klebsiella spp and Acinetobacter spp) infections and D. Leukemia. Hub CCR1 and four interactors (e.g, CCL15, CCL26, CCL8 and TPST1) showed unique co-expression patterns (lower PCC values corresponding to correlated expression between protein pairs) specific to S. Typhi infection.
Figure 3Network of the interacting partners of IRS2 representing differences in dynamic network properties in S. Typhi infection.
The edges were labelled with respective PCC values of individual interactors during different perturbances. The four mentioned conditions are A. Control (normal host cell), B. S. Typhi infection, C. other bacteremic (non-typhoid Salmonella, Klebsiella spp and Acinetobacter spp) infections, D. Leukaemia. Hub IRS2 and five interactors (e.g, IL4R, JAK3, PIK3CD, SHC1 and TYK2) showed unique co-expression pattern (lower PCC values corresponding to correlated expression between protein pairs) specific to S. Typhi infection.